# Eli Lilly and share price today (Eli Lilly and Company, LLY)

> Eli Lilly and Company's results are improving, while its P/E is near the low end of its own history over 4.6 years, higher than only 24% of past readings. LLY · Healthcare · Drug Manufacturers - General · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/lly

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: $1,418 (+53.4% in a year)
- P/E: 46.0× (lower than 76% of the last 4.6 years)
- Revenue (Sep 2026): $24.4 B (+38.6% on a year ago)
- Profit (Sep 2026): $6.5 B (+15.6% on a year ago)
- Operating margin: 53.7% (+5.4 points on a year ago)
- ROE: 78%, FY25
- ROIC: 42.7%, against a 6.2% cost of capital: +36.5 points

The main question: yearly earnings per share moved +96.0% while the share price moved +53.4%. ## What is the Eli Lilly and share price today? Eli Lilly and Company's share price was $1,418 at the close on 4 November 2026. It has been rising for 28 weeks. That is 29.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between $878 and $1,418, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 4 weeks in a row. Over the last 10 years the share price moved +1,680% while the S&P 500 moved +261%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Eli Lilly and pay? Eli Lilly and Company paid $6.69 per share over the last four reported quarters. The most recent declaration was $1.73 for Sep 2026. At today's price of $1,418 that is a yield of 0.47%, based on dividends already paid, not a forecast. ## Which stock lists is Eli Lilly and on? Eli Lilly and is on one of our US lists: S&P 500 companies. [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is Eli Lilly and profitable? Eli Lilly and Company earned $6.5 B of net profit in the Sep 2026 quarter, +15.6% on the same quarter a year earlier. That is the 8th quarter in a row of profit growth. Full-year FY25 profit was $20.6 B. Over 4 years profit has grown 38.7% a year on average. That is 26.4% of the quarter's revenue. The same quarter a year earlier earned $5.6 B. For the full year, FY25 profit was $20.6 B (+94.9% on the year before). Why profit moved: revenue changed +38.6% on a year earlier and the margin moved +5.4 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +64.9% and revenue +46.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Eli Lilly and make, and is it growing? Eli Lilly and Company reported $24.4 B of revenue in the Sep 2026 quarter, +38.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 23.2% a year on average. The last full year, FY25, came in at $65.2 B. The last four reported quarters add to $86.5 B. FY25 revenue was $65.2 B, +44.7% on the year before. Recent pace: the last four quarters grew +46.1% on average, against 23.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +45.5%, against +45.5% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +49.8%, against +81.5% a year (rolling over). ## How much of every $100 of sales does Eli Lilly and keep? Eli Lilly and Company's operating margin was 53.7% in the Sep 2026 quarter, 5.4 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 29.2% and 45.6%. The latest quarter is above every full year in that period. Across 5 years it has been between 29.2% and 45.6%, and FY25's 45.6% is the highest of them. Why the margin moved: operating margin changed +5.4 percentage points on the year while gross margin changed +1.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Eli Lilly and's profit turning into cash? Over the last 3 years, 82% of Eli Lilly and Company's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $16.8 B of operating cash against $20.6 B of profit. After $7.8 B of spending on assets, $9.0 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Eli Lilly and's cash go? Eli Lilly and Company does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $16.3 B on assets over the last 3 years. Averaged over those years that is 8.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $16.3 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Eli Lilly and's P/E ratio, and how does it compare with its own history? Eli Lilly and Company's P/E is 46.0×, near the low end of its own history: it has been lower only 24% of the time. Its usual P/E (the middle reading) is 54.9×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +96.0% while the price moved +53.4%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +35.7% a year; about +77.4% a year came from earnings growth and about −41.7 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Eli Lilly and business getting better or worse? Eli Lilly and Company's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +120.0% at its peak to +49.8%, but the business is still expanding, with ROCE rising at 52.0%. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Eli Lilly and earn on its capital? Eli Lilly and Company earned a ROE of 78% in FY25. That is up from a low of 48% in FY23. Its return on capital used (ROIC) is 36.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 31.7% net margin and 0.58× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 31.7% net margin × 0.58× asset turnover × 4.24× leverage (assets divided by equity) ≈ 78.0% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 42.7% − 6.2% = +36.5 percentage points. The 6.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 42.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 43.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Eli Lilly and have too much debt? Eli Lilly and Company has total debt of $54.9 B against shareholder equity of $33.9 B as of Sep 2026, so its debt is 1.62× its equity. Year by year, that ratio went from 1.85 in FY21 to 1.65 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Eli Lilly and shareholding pattern? 0.8% of Eli Lilly and Company's tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 3.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Eli Lilly and from balance-sheet trouble? For Eli Lilly and Company, the Z-score is 7.27. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 7.27 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Eli Lilly and rank in its industry? 83.3 out of 100, rank 1 of 16 in Drug Manufacturers - General, with 85% of the evidence available. Eli Lilly and Company scores 83.3 out of 100 against the 16 companies it is compared with in Drug Manufacturers - General, ranking 1. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 32 + 21.4 + 11.9 + 18 = 83.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Eli Lilly and compared with? Eli Lilly and ranks 1 of 16 Drug Manufacturers - General companies on the 4-Factor Sector Score, with 83.3 out of 100. 1. Eli Lilly and Company this page LLY · turning · Sector-leading setup · 85% evidence 83.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.0/35 · Revenue 45.5% · Profit 49.8% · Operating margin change 5.4 points · 95% evidence Capital efficiency 21.4/25 · ROCE 41.7% · Operating margin 53.7% · 76% evidence Valuation 11.9/20 · P/E 37.4× · PEG 0.74 · 65% evidence Relative strength 18.0/20 · Lead over its industry 12.9% · Lead over S&P 500 21.8% · 1 year 53.4% · 100% evidence · 3 of 12 weeks ahead Exact sum: 32 + 21.4 + 11.9 + 18 = 83.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [AbbVie Inc.](https://www.sectoralpha.in/us/stocks/abbv) ABBV · breaking out · Most evidence points up · 85% evidence 69.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.8/35 · Revenue 10.7% · Profit 100% · Operating margin change 1.8 points · 95% evidence Capital efficiency 19.4/25 · ROCE 24.5% · Operating margin 37.3% · 76% evidence Valuation 4.4/20 · P/E 44.8× · PEG 2.67 · 65% evidence Relative strength 16.7/20 · Lead over its industry 8.5% · Lead over S&P 500 17% · 1 year 34.5% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28.8 + 19.4 + 4.4 + 16.7 = 69.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Amgen Inc.](https://www.sectoralpha.in/us/stocks/amgn) AMGN · leader · Most evidence points up · 81% evidence 69.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 9.1% · Profit 32.1% · Operating margin change 2.9 points · 83% evidence Capital efficiency 15.2/25 · ROCE 18.2% · Operating margin 35.5% · 76% evidence Valuation 13.1/20 · P/E 22.4× · PEG 0.71 · 65% evidence Relative strength 16.8/20 · Lead over its industry 12.9% · Lead over S&P 500 21.6% · 1 year 49.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24.2 + 15.2 + 13.1 + 16.8 = 69.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Gilead Sciences, Inc.](https://www.sectoralpha.in/us/stocks/gild) GILD · leader · Evidence leans up · 75% evidence 63.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6.5% · Profit -147.6% · Operating margin change -1.8 points · 95% evidence Capital efficiency 19.4/25 · ROCE 30.3% · Operating margin 43.4% · 76% evidence Valuation 11.5/20 · P/E -47.8× · PEG n/a · 15% evidence Relative strength 17.6/20 · Lead over its industry 10.3% · Lead over S&P 500 18.8% · 1 year 46.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.6 + 19.4 + 11.5 + 17.6 = 63.1 · What this means: Relative strength against the index is 18.8%, and revenue and profit growth are weak. 5. [GSK plc](https://www.sectoralpha.in/us/stocks/gsk) GSK · quiet · Evidence leans up · 81% evidence 60.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 5% · Profit 32.1% · Operating margin change 0.9 points · 83% evidence Capital efficiency 19.8/25 · ROCE 25.1% · Operating margin 30.9% · 76% evidence Valuation 14.5/20 · P/E 16.4× · PEG 0.39 · 65% evidence Relative strength 1.4/20 · Lead over its industry -14% · Lead over S&P 500 -7.3% · 1 year 9.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25 + 19.8 + 14.5 + 1.4 = 60.7 · What this means: Earnings are strong; relative strength in its sector is -14% and the one-year return is 9.7%. 6. [Bristol-Myers Squibb Company](https://www.sectoralpha.in/us/stocks/bmy) BMY · turning · Evidence leans up · 81% evidence 59.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 3.1% · Profit 83.8% · Operating margin change 0.7 points · 83% evidence Capital efficiency 18.1/25 · ROCE 22.7% · Operating margin 34.4% · 76% evidence Valuation 14.3/20 · P/E 12.7× · PEG 0.5 · 65% evidence Relative strength 4.7/20 · Lead over its industry -4.8% · Lead over S&P 500 2.7% · 1 year 37.5% · 100% evidence · 5 of 12 weeks ahead Exact sum: 22.6 + 18.1 + 14.3 + 4.7 = 59.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Sanofi](https://www.sectoralpha.in/us/stocks/sny) SNY · turning · Evidence leans up · 66% evidence 51.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/35 · Revenue n/a · Profit n/a · Operating margin change 5.1 points · 39% evidence Capital efficiency 9.2/25 · ROCE 10.7% · Operating margin 21% · 76% evidence Valuation 14.5/20 · P/E 22.8× · PEG 0.33 · 65% evidence Relative strength 7.3/20 · Lead over its industry -9.4% · Lead over S&P 500 -2.2% · 1 year -4.4% · 100% evidence · 1 of 12 weeks ahead Exact sum: 20.6 + 9.2 + 14.5 + 7.3 = 51.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [AstraZeneca PLC](https://www.sectoralpha.in/us/stocks/azn) AZN · turning · Evidence leans up · 85% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.2/35 · Revenue 7.3% · Profit 17.4% · Operating margin change 3 points · 95% evidence Capital efficiency 14.2/25 · ROCE 17.6% · Operating margin 27.1% · 76% evidence Valuation 10.0/20 · P/E 22.9× · PEG 1.33 · 65% evidence Relative strength 7.1/20 · Lead over its industry -9.6% · Lead over S&P 500 -2.6% · 1 year 13.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 19.2 + 14.2 + 10 + 7.1 = 50.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Organon & Co.](https://www.sectoralpha.in/us/stocks/ogn) OGN · turning · Evidence leans down · 81% evidence 48.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.3/35 · Revenue -2.5% · Profit -70.1% · Operating margin change -0.9 points · 83% evidence Capital efficiency 10.8/25 · ROCE 11.5% · Operating margin 20.7% · 76% evidence Valuation 15.5/20 · P/E 17× · PEG 0.17 · 65% evidence Relative strength 12.4/20 · Lead over its industry 11.7% · Lead over S&P 500 20.9% · 1 year 104% · 100% evidence · 0 of 12 weeks ahead Exact sum: 9.3 + 10.8 + 15.5 + 12.4 = 48 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 10. [Novartis AG](https://www.sectoralpha.in/us/stocks/nvs) NVS · turning · Evidence leans down · 85% evidence 46.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.4/35 · Revenue 1.8% · Profit -30.4% · Operating margin change 3.4 points · 95% evidence Capital efficiency 18.4/25 · ROCE 21.6% · Operating margin 34.3% · 76% evidence Valuation 6.4/20 · P/E 27.2× · PEG 2.3 · 65% evidence Relative strength 7.4/20 · Lead over its industry -3.8% · Lead over S&P 500 3.7% · 1 year 30.6% · 100% evidence · 1 of 12 weeks ahead Exact sum: 14.4 + 18.4 + 6.4 + 7.4 = 46.6 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [Johnson & Johnson](https://www.sectoralpha.in/us/stocks/jnj) JNJ · turning · Evidence leans down · 75% evidence 46.6 out of 100 Growth Capital Valuation Relative
12. [Biogen Inc.](https://www.sectoralpha.in/us/stocks/biib) BIIB · breaking out · Evidence leans down · 81% evidence 46.1 out of 100 Growth Capital Valuation Relative
13. [Pfizer Inc.](https://www.sectoralpha.in/us/stocks/pfe) PFE · leader · Evidence leans down · 71% evidence 44.1 out of 100 Growth Capital Valuation Relative
14. [Merck & Co., Inc.](https://www.sectoralpha.in/us/stocks/mrk) MRK · leader · Evidence leans down · 85% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Grifols, S.A.](https://www.sectoralpha.in/us/stocks/grfs) GRFS · turning · Evidence leans down · 71% evidence 40.6 out of 100 Growth Capital Valuation Relative
16. [Amarin Corporation plc](https://www.sectoralpha.in/us/stocks/amrn) AMRN · basing · Most evidence points down · 64% evidence 28.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - General](https://www.sectoralpha.in/us/sectors/drug-manufacturers-general), all 16 compared on one page. ## Which companies are close to Eli Lilly and in size? Eli Lilly and is the largest of 17 Drug Manufacturers - General companies on Sector Alpha by market value (scores of 4 November 2026). It is the largest. Just below it: Johnson & Johnson, AbbVie Inc., Merck & Co., Inc., Novartis AG, AstraZeneca PLC and Amgen Inc. ### Drug Manufacturers - General companies close in size

1. Eli Lilly and Company $1.26 trillion
2. [Johnson & Johnson](https://www.sectoralpha.in/us/stocks/jnj) $665.3 billion
3. [AbbVie Inc.](https://www.sectoralpha.in/us/stocks/abbv) $520.9 billion
4. [Merck & Co., Inc.](https://www.sectoralpha.in/us/stocks/mrk) $371 billion
5. [Novartis AG](https://www.sectoralpha.in/us/stocks/nvs) $310.3 billion
6. [AstraZeneca PLC](https://www.sectoralpha.in/us/stocks/azn) $301 billion
7. [Amgen Inc.](https://www.sectoralpha.in/us/stocks/amgn) $258.6 billion

[All 17 Drug Manufacturers - General companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-general#all-companies)

### Companies close in size in other industries

1. [Broadcom Inc.](https://www.sectoralpha.in/us/stocks/avgo) $1.55 trillion · Semiconductors
2. [Tesla, Inc.](https://www.sectoralpha.in/us/stocks/tsla) $1.52 trillion · Auto Manufacturers
3. Eli Lilly and Company $1.26 trillion
4. [Berkshire Hathaway Inc.](https://www.sectoralpha.in/us/stocks/brk-b) $1.24 trillion · Insurance - Diversified
5. [Walmart Inc.](https://www.sectoralpha.in/us/stocks/wmt) $1.03 trillion · Discount Stores

## What else do people ask about Eli Lilly and? ### What is Eli Lilly and's stock price today? Eli Lilly and Company's stock price is $1,418, +53.4% over the past year. The whole company is worth $1,263 B on the market. It is at its highest price of the past 52 weeks (range $878 to $1,418), 29.2% above its 200-day average. The price has been rising for 28 weeks (as of 4 November 2026). ### What were Eli Lilly and's latest quarterly results? Eli Lilly and Company reported revenue of $24.4 B and net profit of $6.5 B for the Sep 2026 quarter. Revenue rose 38.6% and profit rose 15.6% compared with a year earlier. Earnings per share were $7.22. The operating margin was 53.7%, 5.4 percentage points higher than a year earlier (as of 4 November 2026). ### What is Eli Lilly and's market cap? Eli Lilly and Company's market capitalisation is $1,263 B at a stock price of $1,418. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Eli Lilly and performing? Eli Lilly and Company's share price has been rising for 28 weeks. In its latest quarter, revenue rose 38.6% and profit rose 15.6% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 4 weeks running (as of 4 November 2026). ### Will Eli Lilly and's stock price go up? This page does not forecast Eli Lilly and Company's stock price. What it shows instead: the stock price is $1,418, and it has been rising for 28 weeks. Its P/E of 46.0× is higher than 24% of its own last 5 years (as of 4 November 2026). ### Does Eli Lilly and have too much debt? Yes, Eli Lilly and Company has a lot of debt: its debt is 1.23× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 4 November 2026). ### Where is Eli Lilly and in its business cycle? Eli Lilly and Company's FY25 operating margin was 45.6%, against a 5-year range of 29.2% to 45.6%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 53.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Eli Lilly and story? The main question: yearly earnings per share moved +96.0% while the share price moved +53.4%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Eli Lilly and a stock worth studying right now? What the numbers show: Eli Lilly and Company's results are improving, while its P/E is near the low end of its own history over 4.6 years, higher than only 24% of past readings. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.